S&P 500   3,840.58
DOW   31,149.47
QQQ   322.65
S&P 500   3,840.58
DOW   31,149.47
QQQ   322.65
S&P 500   3,840.58
DOW   31,149.47
QQQ   322.65
S&P 500   3,840.58
DOW   31,149.47
QQQ   322.65
Log in

Proteostasis Therapeutics Stock Forecast, Price & News

-0.57 (-2.59 %)
(As of 01/15/2021)
Today's Range
Now: $21.43
50-Day Range
MA: $10.08
52-Week Range
Now: $21.43
Volume40,237 shs
Average Volume1.04 million shs
Market Capitalization$1.12 billion
P/E RatioN/A
Dividend YieldN/A
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Proteostasis Therapeutics logo


Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 1.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PTI



Sales & Book Value

Annual Sales$5 million
Book Value$1.22 per share


Net Income$-59,130,000.00


Market Cap$1.12 billion
Next Earnings Date3/9/2021 (Estimated)
-0.57 (-2.59 %)
(As of 01/15/2021)
30 days | 90 days | 365 days | Advanced Chart

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

How has Proteostasis Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PTI shares have increased by 1,747.4% and is now trading at $21.43.
View which stocks have been most impacted by COVID-19

Is Proteostasis Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Proteostasis Therapeutics stock.
View analyst ratings for Proteostasis Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Proteostasis Therapeutics?

Wall Street analysts have given Proteostasis Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Proteostasis Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Proteostasis Therapeutics

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) posted its earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01.
View Proteostasis Therapeutics' earnings history

What price target have analysts set for PTI?

4 Wall Street analysts have issued 12 month price targets for Proteostasis Therapeutics' shares. Their forecasts range from $3.00 to $7.00. On average, they expect Proteostasis Therapeutics' share price to reach $4.67 in the next year. This suggests that the stock has a possible downside of 78.2%.
View analysts' price targets for Proteostasis Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Proteostasis Therapeutics' key competitors?

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the following people:
  • Ms. Meenu Chhabra, Pres, CEO & Director (Age 48, Pay $844.78k)
  • Dr. Marija Zecevic, Chief Commercial Officer (Age 46, Pay $530.46k)
  • Michael L. Alfieri, Head of Fin.
  • Dr. Benito Munoz, Chief Scientific Officer (Age 58)
  • Ms. Janet L. Smart Esq., Ph.D., J.D., Sr. VP of Legal Affairs (Age 63)
  • Dr. Geoffrey S. Gilmartin, Chief Medical Officer (Age 52)
  • Ms. Claudia Styslinger, Investor Relations Exec.

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $21.43.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $1.12 billion and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is www.proteostasis.com.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.